Immunicon Releases ASCO 2007 Podium Presentations

Business Wire, June 7, 2007

Multi-Center Studies Clearly Demonstrate Clinical Utility of CTCs across Colorectal, Breast and Prostate Cancers

HUNTINGDON VALLEY, Pa. -- Immunicon Corporation (NASDAQ-GM:IMMC) has released highlights from podium presentations made at the 43rd Annual American Society of Clinical Oncology (ASCO) meeting June 1-5 in Chicago. These presentations describe the results of multi-center, international clinical trials of patients with advanced prostate and colorectal cancers, and the use of Circulating Tumor Cell (CTC) measurement to predict patient survival and as an aid to select patients for and monitor the effectiveness of the targeted therapy. The presentations can be viewed from www.asco.org

The study presented by Neal J. Meropol, MD, director of the Gastrointestinal Cancer Program at Fox Chase Cancer Center, discussed findings that showed that CTCs are the strongest independent predictor of survival in patients with metastatic colorectal cancer, and that patients with Favorable CTC after 3-5 weeks of therapy lived more than 3 times as long as those with Unfavorable CTC. Dr. Meropol noted that new treatment options for metastatic colorectal cancer have recently expanded, highlighting the need for biomarkers to guide and monitor therapy.

In the study presented by Jose Moreno, MD, clinical associate professor of Urology at Thomas Jefferson University, CTC measurement after initiation of therapy in men with hormone refractory prostate cancer were highly predictive of outcome and delivered more reliable information about patient survival than the change in Prostate-Specific Antigen (PSA) at all of the time points tested. Dr. Moreno's presentation included the comparative information on the clinical significance of CTC's and he commented that this is the third prospective pivotal study showing the prognostic and predictive value of CTCs in metastatic carcinomas.

In Monday's Clinical Science Symposium, Johan de Bono MD FRCP MSc PhD, Senior Lecturer and Consultant at the Institute of Cancer Research of the Royal Marsden Hospital, in the UK highlighted the need for CTC studies to explore patient selection, particularly in advanced refractory prostate cancer and emphasized the potential value of CTCs in assessing pharmacodynamics and tumor resistance. Dr. de Bono used results from Pfizer's Phase I, II CP-751,871 studies targeting IGF1-R and results from Abiraterone (CYP17i) Phase I/II study targeting the androgen receptor in which CTC measurement was used in combination with Fluorescence In-situ Hybridization to support his conclusions.

Byron D. Hewett, CEO and President of Immunicon Corporation commented, "Since the CellSearch[TM] Circulating Tumor Cell Test received FDA-clearance in December 2006 for monitoring patients with advanced breast cancer, we have been encouraged by studies showing the clinical utility of CTC measurement across metastatic breast, prostate and colorectal cancers. Regardless of the type of therapy, line of therapy, or time of sampling, CTC have been shown to be clinically significant across a variety of carcinomas."

At ASCO, there were eleven abstracts or posters presented that utilized Immunicon's CellTracks[R] technology. The 43rd annual ASCO conference, the premier educational and scientific event in the oncology community, began Friday, June 1st and closed Tuesday, June 5. More information about ASCO can be found at www.asco.org.

About Immunicon Corporation

Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, and is providing certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon's products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as "hope," "may," "believe," "anticipate," "plan," "expect," "intend," "assume," "will" and similar expressions. Forward-looking statements contained in this press release include, among others, statements regarding the anticipated clinical utility of Immunicon's products and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, are based on the current expectations and intent of the management of Immunicon and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by these statements. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, including, but not limited to, risks and uncertainties associated with: Immunicon's dependence on Veridex, LLC, a Johnson & Johnson company, in the field of cancer cell analysis; the ability to earn license and milestone payments under Immunicon's agreement with Veridex; Immunicon's capital and financing needs; research and development and clinical trial expenditures; commercialization of product candidates; Immunicon's ability to obtain licenses from third parties to commercialize products; Immunicon's ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon's customers; compliance with applicable manufacturing standards; retaining key personnel; delays in the development of new products or planned improvements to products; effectiveness of products compared to competitors' products; protection of Immunicon's intellectual property; conflicts with third party intellectual property; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon's industry. These factors are discussed in more detail in Immunicon's filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services.